The current advancements in chitosan nanoparticles in the management of non-surgical periodontitis treatment.

Because of the intricate interactions between bacteria internalization in periodontal cells and chronic inflammatory activation, periodontal disorders remain difficult. Furthermore, the primary cause of adult tooth loss is periodontitis, one of the most common dental disorders worldwide. The key to preventing periodontitis has been to reduce the development of bacteria and the generation of substances that eventually erode the tissue surrounding and supporting the teeth. Furthermore, there are several disadvantages to treating periodontitis with antibiotics administered systemically. A naturally occurring polymer with antibacterial and anti-inflammatory properties is chitosan (CS). CS is highly interested in treating periodontal disease as a medicine carrier due to its actions against anaerobic microorganisms and possible anti-inflammatory properties. Due to the multifactorial pathophysiology of periodontitis, combining antimicrobial medications in a single drug delivery method is preferable to administering them separately since it increases the therapeutic range when numerous organisms are present. As a result, CS-based drug delivery technologies, such as gels, micro, and nanoparticles (NPs), were created to transport drugs to the periodontal pocket over an extended period. This research provides an overview of the existing therapeutic benefits of CSNP on periodontitis. This information might be used to create therapeutic substitutes based on CSNP for treating periodontal infections.